

# NCCP advice for medical professionals on the management of patients undergoing Prostate Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) pandemic

---

**This document relates to patients who do not have COVID-19 or are not suspected of having COVID-19.**

**Current events surrounding the COVID 19 pandemic are challenging and all public health bodies are placing the safety of patients, staff and communities first in all decisions.**

**This is an evolving situation. This advice is based on current information, it is additional to the advice of the NPHET, the HSE and the DoH, and will be updated as necessary.**

**The NCCP acknowledges that each hospital is working under individual constraints, including staff and infrastructure, and as a result will implement this advice based on their own unique circumstances.**

**The purpose of this advice is to maximise the safety of patients and make the best use of HSE resources, while protecting staff from infection. It will also enable services to match the capacity for cancer care to patient needs if services become limited due to the COVID-19 pandemic.**

**Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment.**

## 1 NPHET, HSE and DoH advice

Hospitals will operate under the overarching advice of the National Public Health Emergency Team (NPHET), the HSE and the DoH. Information is available at:

- HSE HPSC - <https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/guidance/>
- HSE Coronavirus (COVID-19) - <https://www2.hse.ie/conditions/coronavirus/coronavirus.html>
- DoH Coronavirus (COVID-19) - <https://www.gov.ie/en/campaigns/c36c85-covid-19-coronavirus/>
- Ireland's National Action Plan in response to COVID-19 (Coronavirus) - <https://www.gov.ie/en/campaigns/c36c85-covid-19-coronavirus/>

## 2 Purpose

The purpose of this guidance document is to provide guidance to medical professionals on the management of patients undergoing Prostate Cancer Radiotherapy during the COVID-19 pandemic.

In general prostate cancers are either low risk and delaying treatment does not impact outcomes or patients hormone treatment can be continued, keeping the cancer controlled.

### 3 Risk stratification of prostate cancer patients

**Table 1** Risk stratification (NCCN, 2020)

<b>Risk group</b>	<b>Clinical/pathologic features</b>	
<b>Very Low</b>	Has all of the following: <ul style="list-style-type: none"> <li>• T1c</li> <li>• Grade Group 1</li> <li>• PSA &lt;10 ng/mL</li> <li>• Fewer than 3 prostate biopsy fragments/cores positive, ≤50% cancer in each fragment/core</li> <li>• PSA density &lt;0.15 ng/mL/g</li> </ul>	
<b>Low</b>	Has all of the following but does not qualify for very low risk: <ul style="list-style-type: none"> <li>• T1-T2a AND</li> <li>• Grade Group 1 AND</li> <li>• PSA &lt;10 ng/mL</li> </ul>	
<b>Intermediate</b>	Has all of the following: <ul style="list-style-type: none"> <li>• No high-risk group features</li> <li>• No very-high-risk group features</li> <li>• Has one or more intermediate risk factors (IRF):               <ul style="list-style-type: none"> <li>○ T2b-T2c</li> <li>○ Grade Group 2 or 3</li> <li>○ PSA 10–20 ng/mL</li> </ul> </li> </ul>	<p><b>Favorable intermediate</b></p> <p>Has all of the following:</p> <ul style="list-style-type: none"> <li>• 1 IRF and</li> <li>• Grade Group 1 or 2 and</li> <li>• &lt;50% biopsy cores positive</li> </ul> <p><b>Unfavorable intermediate</b></p> <p>Has one or more of the following:</p> <ul style="list-style-type: none"> <li>• 2 or 3 IRFs</li> <li>• Grade Group 3</li> <li>• &gt;50% biopsy cores positive</li> </ul>
	<p><b>High</b></p> <p>Has no very-high-risk features and has at least one high-risk feature:</p> <ul style="list-style-type: none"> <li>• T3a OR</li> <li>• Grade Group 4 or Grade Group 5 OR</li> <li>• PSA &gt;20 ng/mL</li> </ul>	
<b>Very High</b>	Has at least one of the following: <ul style="list-style-type: none"> <li>• T3b–T4</li> <li>• Primary Gleason pattern 5</li> <li>• 2 or 3 high-risk features</li> <li>• • &gt;4 cores with Grade Group 4 or 5</li> </ul>	

## 4 Recommendations for prostate cancer radiotherapy during the COVID-19 pandemic

<b>Risk group</b>	<b>Radiotherapy recommendations</b>
<b>Very Low</b>	Treat as per National Guidelines
<b>Low</b>	Treat as per National Guidelines
<b>Intermediate</b>	
Favourable intermediate	Treat as per National Guidelines
Unfavourable intermediate	Treat as per National Guidelines
<b>High</b>	Treat as per National Guidelines
<b>Very High</b>	Treat as per National Guidelines

- This is guidance and it is expected that individual circumstances of patients will have to be taken into account by the treating clinician.
- This guidance may change in line with the 'NCCP advice on radiation therapy capacity escalation plan in response to the current COVID 19 pandemic'.

## 5 Guidance Development Group

- Dr Cormac Small - Consultant Radiation Oncologist
- Dr Brian O'Neill - Consultant Radiation Oncologist
- Dr Aileen Flavin - Consultant Radiation Oncologist
- Dr Eve O'Toole - Guideline Lead, NCCP
- Ms Ruth Ryan - Programme Manager, NCCP
- Ms Louise Murphy - Research Officer, NCCP